[go: up one dir, main page]

MX2019008974A - Vacunas contra el coronavirus porcino. - Google Patents

Vacunas contra el coronavirus porcino.

Info

Publication number
MX2019008974A
MX2019008974A MX2019008974A MX2019008974A MX2019008974A MX 2019008974 A MX2019008974 A MX 2019008974A MX 2019008974 A MX2019008974 A MX 2019008974A MX 2019008974 A MX2019008974 A MX 2019008974A MX 2019008974 A MX2019008974 A MX 2019008974A
Authority
MX
Mexico
Prior art keywords
pdcov
pedv
porcine
inactivated
virus
Prior art date
Application number
MX2019008974A
Other languages
English (en)
Inventor
Martin Vaughn Eric
Rae Patterson Abby
Gilbert Victoria Joseph
V Iyer Arun
Ralph HERMANN Joseph
Ann Hobbs Lea
ACKERMAN Scott
Alejandro Hernandez Luis
O''conner Sean
Original Assignee
Boehringer Ingelheim Animal Health Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health Usa Inc filed Critical Boehringer Ingelheim Animal Health Usa Inc
Publication of MX2019008974A publication Critical patent/MX2019008974A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una vacuna para proteger un cerdo contra enfermedades asociadas a la infección por coronavirus, que incluye el virus de la diarrea epidémica porcina (PEDV) y/o el deltacoronavirus porcino (PDCoV). La vacuna incluye comúnmente PEDV inactivado/suprimido (por ejemplo, virus de PED químicamente inactivado) y/o antígeno de PEDV recombinante, y/o un PDCoV inactivado/suprimido adyuvante (por ejemplo, virus PDCoV químicamente inactivado), y/o antígeno de PDCoV recombinante y un adyuvante. También se proporcionan métodos para proteger cerdos contra enfermedades asociadas a PEDV y/o PDCoV y metodos para producir la vacuna contra el virus de la diarrea epidémica porcina y/o el deltacoronavirus porcino.
MX2019008974A 2017-01-30 2018-01-26 Vacunas contra el coronavirus porcino. MX2019008974A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452026P 2017-01-30 2017-01-30
PCT/US2018/015507 WO2018140766A2 (en) 2017-01-30 2018-01-26 Porcine coronavirus vaccines

Publications (1)

Publication Number Publication Date
MX2019008974A true MX2019008974A (es) 2019-10-09

Family

ID=61193105

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008974A MX2019008974A (es) 2017-01-30 2018-01-26 Vacunas contra el coronavirus porcino.

Country Status (11)

Country Link
US (2) US12150983B2 (es)
EP (1) EP3573655A2 (es)
JP (1) JP2020506915A (es)
KR (1) KR20190110605A (es)
CN (1) CN110545841A (es)
AU (1) AU2018212843A1 (es)
CA (1) CA3046684A1 (es)
EA (1) EA201991762A1 (es)
MX (1) MX2019008974A (es)
PH (1) PH12019501766A1 (es)
WO (1) WO2018140766A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109651488A (zh) * 2018-12-21 2019-04-19 广西壮族自治区兽医研究所 猪丁型冠状病毒重组n蛋白及其多克隆抗体的制备方法
KR102213745B1 (ko) * 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
US12502426B2 (en) 2019-12-16 2025-12-23 Intervet Inc. Inactivated piscine orthoreovirus vaccine
CN111187782B (zh) * 2020-01-20 2022-10-14 上海交通大学 猪Delta冠状病毒病毒样颗粒及其制备方法和应用
WO2021209060A1 (en) * 2020-04-17 2021-10-21 Sinovac Research & Development Co., Ltd. Inactivated vaccine for sars-cov-2 and preparation thereof
US20220160866A1 (en) * 2020-10-05 2022-05-26 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
CN112546213A (zh) * 2020-12-31 2021-03-26 中国医学科学院医学生物学研究所 一种制备新型冠状病毒疫苗的方法及针对其有效性的评价方法
CN113698475B (zh) * 2021-07-05 2022-10-11 国药集团动物保健股份有限公司 抗猪δ冠状病毒N蛋白的单克隆抗体和猪δ冠状病毒胶体金快速检测试纸条
CN113480665B (zh) * 2021-07-30 2024-02-06 广州源博医药科技有限公司 一种用于猪流行性腹泻病毒的融合蛋白以及重组蛋白疫苗
CN114395574B (zh) * 2022-01-18 2023-08-11 长沙爱科博生物科技有限公司 一种猪流行性腹泻病毒融合蛋白及其编码基因与应用
CN114994328A (zh) * 2022-04-22 2022-09-02 国药集团动物保健股份有限公司 一种猪δ冠状病毒IgA的检测方法
CN116024244B (zh) * 2022-08-04 2023-09-22 长沙爱科博生物科技有限公司 一种融合蛋白基因及其应用
CN115887633A (zh) * 2022-08-09 2023-04-04 江苏省农业科学院 一种猪δ冠状病毒基因工程亚单位疫苗及其应用
CN116253798B (zh) * 2022-12-15 2023-10-27 华中农业大学 一株针对猪δ冠状病毒S1蛋白构象表位的中和性单克隆抗体
CN116925194B (zh) * 2023-03-17 2024-06-21 四川农业大学 一种猪δ冠状病毒S1蛋白的中和抗原表位及其应用
CN116875562B (zh) * 2023-07-14 2024-06-14 河南农业大学 一株猪δ冠状病毒传代致弱毒株及其应用
CN116850204A (zh) * 2023-08-01 2023-10-10 四川农业大学 一种纳米硒在制备抗猪德尔塔冠状病毒的药物中的应用
CN118515745B (zh) * 2024-04-23 2025-08-05 湖南派智生物科技有限公司 猪丁型冠状病毒的s蛋白突变体、疫苗、细胞株、抗体、方法及应用
CN118994418B (zh) * 2024-08-26 2025-08-01 畜科生物工程有限公司 一种猪丁型冠状病毒s蛋白及重组腺病毒
CN119080921B (zh) * 2024-09-04 2026-01-09 四川农业大学 一种抗猪δ冠状病毒的猪-鼠嵌合抗体及其应用
CN119431526B (zh) * 2024-11-15 2025-11-07 郑州大学 一种猪δ冠状病毒S1-CTD蛋白线性B细胞表位肽及其应用
CN120082601B (zh) * 2025-05-07 2025-08-22 江苏省农业科学院 一种低复制能力的猪流行性腹泻病毒及其构建方法和应用
CN120514838B (zh) * 2025-05-21 2025-11-21 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种可自我切割并表达多个病毒结构蛋白的PDCoV病毒mRNA疫苗及其制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US10280199B2 (en) * 2014-02-07 2019-05-07 Phibro Animal Health Corporation Coronavirus proteins and antigens
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
WO2015179412A1 (en) * 2014-05-19 2015-11-26 Merial, Inc. Recombinant spike protein subunit based vaccine for porcine epidemic diarrhea virus (pedv)
CN104248762B (zh) * 2014-06-24 2017-09-29 普莱柯生物工程股份有限公司 一种猪流行性腹泻疫苗组合物及其制备方法和应用
WO2016000757A1 (de) 2014-07-01 2016-01-07 Siemens Aktiengesellschaft Submodul eines modulartig aufgebauten bremsstellers, bremssteiler und ein verfahren zum betreiben des bremsstellers
HRP20211451T1 (hr) * 2014-07-11 2021-12-24 Zoetis Services Llc Novi cjepivni pripravci protiv virusa svinjske epidemijske dijareje
CN104248462B (zh) 2014-09-24 2016-10-12 浙江海圣医疗器械有限公司 一次性使用桡动脉压迫器

Also Published As

Publication number Publication date
WO2018140766A3 (en) 2018-08-23
CN110545841A (zh) 2019-12-06
KR20190110605A (ko) 2019-09-30
EA201991762A1 (ru) 2020-01-23
AU2018212843A1 (en) 2019-06-27
US20200038504A1 (en) 2020-02-06
US20250082747A1 (en) 2025-03-13
PH12019501766A1 (en) 2020-06-15
CA3046684A1 (en) 2018-08-02
WO2018140766A2 (en) 2018-08-02
EP3573655A2 (en) 2019-12-04
US12150983B2 (en) 2024-11-26
JP2020506915A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
MX2019008974A (es) Vacunas contra el coronavirus porcino.
MX2016012845A (es) Vacuna contra el virus de la diarrea epidemica porcina.
MX2021012695A (es) Vacuna de subunidad del virus de la fiebre porcina clasica (csfv).
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
CO6551750A2 (es) Vacuna del virus del dengue inactivado que incluye un adyuvante sin aluminio
CR20150170A (es) Vacunas de inmersión subunidad para peces
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112017002496A2 (pt) agente de controle contra a síndrome reprodutiva e respiratória porcina
ZA202101173B (en) Composition containing influenza vaccine
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
BR112018010679A2 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
BR112021019028A2 (pt) Uma vacina para proteção contra streptococcus suis
CL2024003284A1 (es) Virus para vacuna contra el síndrome respiratorio y reproductivo porcino.
WO2020012428A8 (en) New vaccines against avian reoviruses
MX381745B (es) Vacunas de pestivirus para temblores congenitos.
MX371126B (es) Vacuna para cerdos contra el sindrome reproductivo y respiratorio porcino y lawsonia intracellularis.
CO2018008184A2 (es) Virus de vacuna del síndrome respiratorio y reproductivo porcino
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
CO2022007006A2 (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar
EA202190351A1 (ru) Композиция, входящая в состав вакцины против гриппа
AR133762A1 (es) Composiciones de arn para la administración de antígenos de mpox y métodos relacionados
TH169741A (th) วัคซีนไวรัสก่อโรคท้องเสียที่ระบาดในหมู
BR112018007918A2 (pt) vacina, uso de antígeno de lawsonia intracellularis inativada, e, método para proteger um animal.